Screener
CytomX Therapeutics CTMX Asset turnover
Asset turnover at other companies
Other financials
Where this comes from
Calculated from CytomX Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
FAQ
- What is CytomX Therapeutics's asset turnover?
- CytomX Therapeutics (CTMX) reported asset turnover of 0.1× in Q2 2026.
- How has CytomX Therapeutics's asset turnover changed year-over-year?
- CytomX Therapeutics's asset turnover decreased by 92.2% year-over-year, from 0.8× to 0.1×.
- What is the long-term trend for CytomX Therapeutics's asset turnover?
- Over 5 years (2020 to 2025), CytomX Therapeutics's asset turnover has grown at a 23.4% compound annual growth rate (CAGR), from 0.2× to 0.6×.
- What does asset turnover mean?
- Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.
Ask your AI about CytomX Therapeutics's asset turnover.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude